Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Grabowski

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Pharmacoeconomics|April 7, 1997
The effect of pharmacoeconomics on company research and development decisionsH Grabowski
Pharmacoeconomics|December 8, 1997
The role of cost-effectiveness analysis in managed-care decisionsH Grabowski
Health Affairs (Project Hope)|January 31, 2002
Useful lessons for policymakersH Grabowski
Health Affairs (Project Hope)|January 1, 1988
Medicaid patients' access to new drugsH Grabowski
Kardiologia Polska|January 1, 1976
[Disappearance of WPW syndrome following myocardial revascularization]H Grabowski
Pharmacoeconomics|December 9, 1995
Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decadeH Grabowski, J Vernon
Wiadomosci Lekarskie (Warsaw, Poland : 1960)|September 15, 1979
[Marfan's syndrome as a cause of ischemic heart disease]A Błaszkowski, H Grabowski
Wiadomosci Lekarskie (Warsaw, Poland : 1960)|October 1, 1977
[Case of recurrent ventricular fibrillation during acute ethanol poisoning]H Grabowski, A Blaszkowski
Wiadomosci Lekarskie (Warsaw, Poland : 1960)|August 1, 1987
[A case of transient suppression of conduction in angina attack]H Grabowski, L Gazda
Social Science & Medicine (1982)|August 1, 1997
Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisionsH Grabowski, C D Mullins
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Pharmacoeconomics|April 7, 1997
The effect of pharmacoeconomics on company research and development decisionsH Grabowski
Pharmacoeconomics|December 8, 1997
The role of cost-effectiveness analysis in managed-care decisionsH Grabowski
Health Affairs (Project Hope)|January 31, 2002
Useful lessons for policymakersH Grabowski
Health Affairs (Project Hope)|January 1, 1988
Medicaid patients' access to new drugsH Grabowski
Kardiologia Polska|January 1, 1976
[Disappearance of WPW syndrome following myocardial revascularization]H Grabowski
Pharmacoeconomics|December 9, 1995
Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decadeH Grabowski, J Vernon
Wiadomosci Lekarskie (Warsaw, Poland : 1960)|September 15, 1979
[Marfan's syndrome as a cause of ischemic heart disease]A Błaszkowski, H Grabowski
Wiadomosci Lekarskie (Warsaw, Poland : 1960)|October 1, 1977
[Case of recurrent ventricular fibrillation during acute ethanol poisoning]H Grabowski, A Blaszkowski
Wiadomosci Lekarskie (Warsaw, Poland : 1960)|August 1, 1987
[A case of transient suppression of conduction in angina attack]H Grabowski, L Gazda
Social Science & Medicine (1982)|August 1, 1997
Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisionsH Grabowski, C D Mullins
Pageof 6